Ophthalmol Eye Dis. 2012 Sep 25;4:79-90. doi: 10.4137/OED.S10294. Print 2012.

Systemic reduction of interleukin-4 or interleukin-10 fails to reduce the frequency or severity of experimental cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression.

Ophthalmology and eye diseases

Emily L Blalock, Hsin Chien, Richard D Dix

PMID: 23650460 PMCID: PMC3619657 DOI: 10.4137/OED.S10294

Abstract

Interleukin-4 (IL-4) and interleukin-10 (IL-10) are key cytokines whose increased production during systemic HIV infection has been associated with decreased cellular immunity during AIDS. We examined whether HIV-induced stimulation of IL-4 or IL-10 production leads to increased susceptibility to AIDS-related human cytomegalovirus retinitis. It was confirmed that there were increased amounts of IL-4 and IL-10 mRNA levels in mice with MAIDS of 10 weeks duration when most susceptible to MCMV retinitis. Surprisingly, however, MCMV-infected eyes of IL-4 -/- and IL-10 -/- mice with MAIDS of 8 weeks duration exhibited retinitis and infectious virus equivalent to that observed in MCMV-infected eyes of wild-type mice with MAIDS. We conclude that neither IL-4 nor IL-10 alone play a role in increased susceptibility to MAIDS-related MCMV retinitis, but may work collectively with other retrovirus-induced immunosuppressive factors to allow for retinal disease.

Keywords: AIDS; MAIDS; cytomegalovirus; interleukin-10; interleukin-4; retinitis

References

1. J Immunol. 2002 Feb 15;168(4):1672-81 - PubMed
2. J Immunol. 2007 Mar 1;178(5):3265-71 - PubMed
3. J Immunol. 1986 Apr 1;136(7):2348-57 - PubMed
4. Immunol Today. 1993 Mar;14(3):107-11 - PubMed
5. Annu Rev Immunol. 2011;29:71-109 - PubMed
6. Science. 1991 Nov 1;254(5032):707-10 - PubMed
7. Am J Ophthalmol. 2011 Feb;151(2):198-216.e1 - PubMed
8. Clin Ophthalmol. 2010 Apr 26;4:285-99 - PubMed
9. J Virol. 1997 Mar;71(3):2518-21 - PubMed
10. Res Immunol. 1994 Oct-Dec;145(8-9):643-5; discussion 645-6 - PubMed
11. Curr Eye Res. 1994 Aug;13(8):587-95 - PubMed
12. J Immunol. 2000 Apr 1;164(7):3487-93 - PubMed
13. Immunology. 2010 Jun;130(2):166-71 - PubMed
14. J Immunol. 2006 Jan 15;176(2):1274-80 - PubMed
15. J Immunol. 1992 Jan 1;148(1):182-8 - PubMed
16. Transplantation. 2008 Feb 15;85(3):437-46 - PubMed
17. J Immunol. 1990 Feb 15;144(4):1331-7 - PubMed
18. Curr Eye Res. 2004 Aug-Sep;29(2-3):91-101 - PubMed
19. J Virol. 2001 Feb;75(3):1205-10 - PubMed
20. Int Rev Immunol. 1998;17(1-4):1-52 - PubMed
21. J Virol. 2005 Jan;79(1):661-7 - PubMed
22. Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H277-84 - PubMed
23. Springer Semin Immunopathol. 1995;17(2-3):231-45 - PubMed
24. Immunol Today. 1996 Mar;17(3):138-46 - PubMed
25. J Immunol. 1988 Feb 15;140(4):1101-6 - PubMed
26. Science. 1993 Jun 18;260(5115):1802-5 - PubMed
27. J Virol. 2003 Mar;77(6):3402-8 - PubMed
28. Invest Ophthalmol Vis Sci. 1997 Jun;38(7):1411-7 - PubMed
29. Curr Eye Res. 2003 Mar-Apr;26(3-4):211-7 - PubMed
30. Eur Cytokine Netw. 1997 Dec;8(4):333-44 - PubMed
31. J Virol. 1995 Aug;69(8):4842-6 - PubMed
32. Crit Rev Immunol. 1997;17(1):1-32 - PubMed
33. PLoS One. 2009 Sep 22;4(9):e7121 - PubMed
34. Science. 1988 May 27;240(4856):1169-76 - PubMed
35. J Virol. 1989 Mar;63(3):1223-31 - PubMed
36. J Virol. 2008 Mar;82(5):2456-69 - PubMed
37. PLoS Med. 2007 Dec;4(12):e334 - PubMed
38. Annu Rev Immunol. 2001;19:683-765 - PubMed
39. Cell. 1993 Oct 22;75(2):263-74 - PubMed
40. J Immunol. 1999 Mar 1;162(5):2488-94 - PubMed
41. Cell Res. 1998 Mar;8(1):1-13 - PubMed
42. J Immunol. 2005 Feb 15;174(4):2021-9 - PubMed
43. Cancer Immunol Immunother. 2007 Oct;56(10):1625-36 - PubMed

Publication Types

• Journal Article

Grant support

• P30 EY006360/EY/NEI NIH HHS/United States
• R01 EY010568/EY/NEI NIH HHS/United States